The lack of FDA pre-market approval means potential risks may not be identified until after widespread consumer use
Its a triple-action medication that mimics the effects of the hormones GLP-1, GIP, and glucagon
Common eligibility criteria may include: BMI of 30 or higher BMI of 27 or higher with at least one weight-related health condition History of failed diet attempts or weight regain Appetite, cravings, or portion control challenges Metabolic risk factors such as insulin resistance, elevated glucose, high cholesterol, or hypertension Need for physician-supervised weight loss due to medical complexity Eligibility must be determined through a medical consultation
These medications should only be used under the supervision of a licensed healthcare provider
The good news is that these sensations appear temporary and do not indicate nerve damage
Supporters argue that the bite in the penalty structure is meant to deter sketchy sourcing and mislabeled products, not to choke off legitimate medical compounding
